First-pass extracted concept

CD38-targeting antibody regimens

Candidate: concept label1 source documents3 linked claims

Jump to explainers Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Extracted Explainers

What the tool is doing

This review describes CD38-targeting antibody regimens as major components of modern multiple myeloma therapy in both frontline and relapsed settings. They are presented as improving response depth and survival outcomes.

Source 1DOI PubMed

What problem it solves

They address the need for more effective regimens in a disease marked by relapse and drug resistance.

Source 1DOI PubMed

What it does not solve

The abstract does not suggest these regimens remove the need for risk-adapted treatment decisions or solve all relapse and resistance problems.

Source 1DOI PubMed

Alternatives

The review contrasts these regimens with PI- and IMiD-based combinations, maintenance strategies, and BCMA-targeted CAR-T therapies.

Source 1DOI PubMed

Evidence Snippets

CD38-targeting antibodies, particularly daratumumab- and isatuximab-based regimens, have demonstrated superior depth of response, prolonged progression-free survival (PFS), and improved overall survival (OS) across transplant-eligible, transplant-ineligible, and relapsed populations.

Evidence 1Source 1DOI PubMedprovenance

Supporting Sources

Source 1review2025MEDDOI PubMed

1 evidence snippet 3 linked claims Claim 1 Claim 2 Claim 3

Linked Claims

Claim 1clinical decision factorsupports2025Source 1DOI PubMed

Therapeutic decisions in multiple myeloma should consider patient frailty, cytogenetic risk, and prior treatment exposure.

Claim 2comparative benefitsupports2025Source 1DOI PubMed

CD38-targeting antibody regimens, especially daratumumab- and isatuximab-based regimens, are associated with superior response depth, prolonged progression-free survival, and improved overall survival across transplant-eligible, transplant-ineligible, and relapsed multiple myeloma populations.

Claim 3review summarysupports2025Source 1DOI PubMed

Phase 3 clinical trials have redefined multiple myeloma management by integrating novel agents, monoclonal antibodies, and cellular therapies into frontline and relapsed/refractory settings.